Bucillamine Phase 2 Trial in Patients With Cystinuria

Phase 2 Multi-Center, Dose Escalation Trial To Assess The Safety And Effectiveness Of Bucillamine On Urinary Cystine Excretion And Cystine Capacity In Patients With Cystinuria

Subjects on a standard regimen of tiopronin (cystine binding thiol drug; CBTD) plus prescribed first-line therapy (i.e. on a hydration, alkali therapy and dietary restriction) who are failing therapy will be selected for this trial.

After completing informed consent, the subject will have Screening consisting of medication history and physical examination with vital signs. Samples of blood and urine will be taken for clinical laboratory and urinalysis. Patients will undergo a 12-lead ECG test. A history of side effects with current CBTD as well as laboratory recordings of abnormalities attributable to treatment will also be recorded.

Subjects will be dosed in a sequential manner, starting with the low dose group (300 mg/day), then proceeding to the 600 mg.day dose group.. Safety and tolerability will be monitored closely by an Independent Medical Monitor (IMM) and based on the IMM's assessment that it is safe to proceed to the higher dose (600 mg/day), subsequent subjects will be enrolled into that group. Up to 15 subjects each will be enrolled into either Group A or Group B.

After 7 days on the assigned bucillamine dose, a 24-hour urine sample will be taken and after completing the Day 8 safety visit, subjects will undergo a 7 day washout where no CBTDs will be taken. Thereafter, subjects will be allowed to resume their originally prescribed CBTDs under Investigator's supervision.

One week following study drug discontinuation, subjects will return to the clinic for follow-up safety assessments.

Study Overview

• Status: Unknown
• Conditions: Cystinuria
• Intervention / Treatment: Drug: Bucillamine

Detailed Description

Subjects on a standard regimen of tiopronin (cystine binding thiol drug; CBTD) plus prescribed first-line therapy (i.e. on a hydration, alkali therapy and dietary restriction) who are failing therapy will be selected for this trial.

Subjects will be encouraged to continue their usual self-selected ad-lib diets, fluid and alkali regimen and keep this regimen consistent throughout the duration of the study. Study diaries will be kept to assess consistency and drug compliance.

After completing informed consent, the enrolled subject will have an initial Screening interview. During the interview the patient will be assessed for symptoms of renal colic as well as asked about any scheduled urological procedures (a positive indication is an exclusionary criteria). At the Screening visit, a medication history will be taken and a complete physical examination, including vital signs will be done. Samples of blood and urine will be taken for clinical laboratory and urinalysis. Patients will then undergo a 12-lead ECG test.

A history of side effects with current CBTD as well as laboratory recordings of abnormalities attributable to treatment will also be recorded.

Enrolled subjects will be dosed in a sequential manner, starting with the low dose group (300 mg/day). Safety and tolerability will be monitored closely by an Independent Medical Monitor (IMM) and based on the IMM's assessment that it is safe to proceed to the higher dose (600 mg/day), subsequent subjects will be enrolled into that group. Up to 15 subjects each will be enrolled into either Group A or Group B.

Subjects will stop taking their current CBTDs for 7 days and perform a 24-hour urine collection on Day-7 and report for Day 1 Visit .

Subjects enrolled into Group A will start taking bucillamine tablets orally, three times a day preferably 1hr before or 2hrs after meals in the following sequence; 100 mg (1 tab) in the morning; 100 mg (1 tab) at noon and 100 mg (1 tab) at night. This drug regimen will continue for 7 days. Safety Visits are scheduled on Day 3 and Day 8 (End of Study Visit). Furthermore, on Day 7 a 24-hour urine collection will be performed. Instructions for handling this sample will be provided in a separate manual.

Subjects enrolled into Group B, will start taking bucillamine tablets orally, three times a day preferably 1hr before or 2hrs after meals in the following sequence; 200 mg (2 tabs) in the morning; 200 mg (2 tabs) at noon and 200 mg (2 tabs) at night. This drug regimen will continue for 7 days. Safety Visits are scheduled on Day 3 and Day 8 (End of Study Visit). Furthermore, on Day 7 a 24-hour urine collection will be performed. Instructions for handling this sample will be provided in a separate manual.

After 7 days on the assigned bucillamine dose and after providing the 24-hour urine sample, and after completing the Day 8 safety visit, subjects will undergo a 7 day washout where no CBTDs will be taken. Thereafter, subjects will be allowed to resume their originally prescribed CBTDs under Investigator's supervision.

One week following study drug discontinuation, subjects will return to the clinic for follow-up safety assessments.

• Study Type: Interventional
• Enrollment (Anticipated): 30
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Fabio Chianelli; Phone Number: 10 905-605-5535; Email: fabio@revivethera.com
• Study Contact Backup: Name: Angela Fuda; Phone Number: 905-605-5535; Email: angela@revivethera.com

Study Locations

• United States
  • Alabama
    • Birmingham, Alabama, United States, 35294
      • Recruiting
      • University of Alabama - Department of Urology
      • Principal Investigator: Dean Assimos, MD
      • Contact: Lisa Harvey; Phone Number: 205-996-2613; Email: lharvey@uabmc.edu
  • Massachusetts
    • Boston, Massachusetts, United States, 02114
      • Recruiting
      • Massachusette General Hospital
      • Contact: Sagar Uday Nigwekar, MD; Phone Number: 617-726-7872; Email: snigwekar@mgh.harvard.edu
  • New York
    • New York, New York, United States, 10016
      • Recruiting
      • New York University School of Medicine
      • Contact: Frank Moderstizki; Phone Number: 6379 212-686-7500; Email: Frank.Moderstizki@nyumc.org
      • Principal Investigator: Lama Nazzal, MD
  • Rhode Island
    • Warwick, Rhode Island, United States, 02886
      • Recruiting
      • Omega Medical Research
      • Contact: Johnna Pezzullo; Phone Number: 401-739-9350; Email: Johnna@omegamedicalresearch.com
      • Principal Investigator: Gyan Pareek, MD
  • Wisconsin
    • Madison, Wisconsin, United States, 53705,
      • Recruiting
      • University of Wisconsin School of Medicane and Public Health
      • Contact: Stephen Nakada, MD; Phone Number: 360-252-2500; Email: nakada@urology.wisc.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Subjects of any gender and of any race ≥18 and ≤80 years of age

2. Subjects with proven cystinuria who are failing their standard drug therapy of tiopronin plus first-line therapy (hydration, alkali and diet restriction) and who meet the following criteria.

   • formed new stones while taking a thiol.
   • had increase in stone size of pre-existing stones while taking a thiol.
   • had a urologic intervention for stones while taking a thiol
3. Subjects must be able to reliably urinate in a collection vessel and measure urine volume
4. Subjects must have documentation of a stable complete blood count (CBC) and urinalysis (UA) in the 6 months prior to date of enrollment
5. Subjects may have a history of but not currently active CNS disorders or symptoms/effects (e.g., headache)

6. Subjects must have adequate organ function, evidenced by the following laboratory results within 30 days prior to enrollment:

   • Absolute neutrophil count >2000 cells/mm
   • Platelet count >140,000 cells/mm3
   • Hemoglobin >11.0 g/dl
   • Albumin ≥2.5 g/dl
   • Total bilirubin ≤1.5 upper limit of normal (ULN)

   • SGOT (aspartate aminotransferase [AST]), SGPT (alanine aminotransferase [ALT]), and alkaline phosphatase (ALP)

     ≤ 2.5 x ULN

   • eGFR >60 ml/min/173m 2 based on Modification of Diet and Renal Disease (MDRD) Study equation which includes the variables of creatinine, age, sex and race
7. Female subject who has been post-menopausal for at least 24 consecutive months, or women who have undergone surgical sterilization, (e.g. hysterectomy, bilateral oophorectomy, tubal ligation or salpingectomy) is eligible without requiring the use of a contraceptive methods described in Inclusion #8

8. For women of childbearing potential and men with partners of childbearing potential, agreement to use a highly effective, non-hormonal form of contraception:

   • Acceptable forms of should include two of the following:

     • Placement of intrauterine device (IUD) or intrauterine system (IUS)
     • Condom with spermicidal foam/gel/film/cream/suppository
     • Diaphragm or cervical/vault caps with spermicidal foam/gel/film/cream/suppository

   • The above contraception is not a requirement in the case of any of the following:

     • Subject is surgically sterilized
     • Subject has had no menstrual period for 12 consecutive months
   • Contraception use should continue for the duration of the study treatment and for at least 3 months after the last dose of study treatment Periodic abstinence (e.g., calendar ovulation, symptom-thermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception
9. Subjects must be willing and able to give written informed consent

Exclusion Criteria:

1. Subjects with renal colic
2. Subjects who are scheduled to undergo a surgical procedure
3. Subjects on D-penicillamine (see page 35 for explanation)
4. Subjects with cancer
5. Subjects with acute or chronic infections including HIV, tuberculosis, hepatitis B or hepatitis C
6. Patients with proteinuria ≥30 mg that is confirmed on repeat laboratory assessment within 24 hours
7. Subjects with QTc interval >450 ms
8. A history of, hypokalemia and family history of Long QT syndrome
9. Use of concomitant medications that may prolong QT/QTc interval
10. Patients with significant heart failure and activity impairment (Class III-IV of the New York Heart Association (NYHA)
11. Subjects with serious hepatic disorder (Child-Pugh scores B or C)
12. Subjects with a history of alcohol or substance abuse within the 12 months prior to enrollment
13. Subjects with history of or active blood dyscrasia such as myelosuppression, leukopenia, granulocytopenia, thrombocytopenia, pancytopenia, and aplastic anemia.
14. Subjects with Coagulopathy (regardless if controlled by pharmacotherapy or not)
15. Subjects who have any concomitant illness (including active significant infection) or other finding that, in the opinion of the Investigator, would confound the study data or place the subject at unacceptable risk if the subject were to participate in the study, or that would require frequent adjustments in concomitant medications during the course of the study
16. Use of any investigational drug within 30 days prior to enrollment
17. Subjects currently participating in another research study or anticipated to enroll in such during participation in this study
18. Subjects for whom informed consent cannot be obtained

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Non-Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Dose Group A; Bucillamine 300 mg/day	Drug: Bucillamine; Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
Experimental: Dose Group B; Bucillamine 600 mg/day	Drug: Bucillamine; Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]	Number, type, and severity of AEs observed by the staff during visits on Days 0 (dosing), 3, 8 and +1 week post-study or volunteered by the subject during telephone follow-up on Days 2 and 7.	Days 0, 2, 3, 7, 8 and + 1 wk post study

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Cystine Excretion	Measurement of 24-hr urine cystine excretion.	Day 0 and Day 8
Cystine Capacity	Measurement of 24-hr urine cystine capacity, i.e., the capacity of a patient's urine to solubilize or precipitate.	Day 0 and Day 8

Collaborators and Investigators

• Sponsor: Revive Therapeutics, Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2017
• Primary Completion (Anticipated): March 1, 2018
• Study Completion (Anticipated): March 1, 2018

Study Registration Dates

• First Submitted: October 19, 2016
• First Submitted That Met QC Criteria: October 20, 2016
• First Posted (Estimate): October 24, 2016

Study Record Updates

• Last Update Posted (Actual): May 18, 2017
• Last Update Submitted That Met QC Criteria: May 16, 2017
• Last Verified: March 1, 2017

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Kidney Diseases; Urologic Diseases; Genetic Diseases, Inborn; Renal Tubular Transport, Inborn Errors; Renal Aminoacidurias; Cystinuria; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Protective Agents; Antioxidants; Bucillamine
• Other Study ID Numbers: REV401

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No